Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Zafgen Inc    ZFGN

ZAFGEN INC (ZFGN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/18/2018 06/19/2018 06/20/2018 06/21/2018 06/22/2018 Date
7.46(c) 7.43(c) 7.33(c) 6.71(c) 7.09(c) Last
204 900 124 738 119 146 252 680 2 281 354 Volume
+5.97% -0.40% -1.35% -8.46% +5.66% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -67,6 M
Net income 2018 -67,6 M
Finance 2018 27,5 M
Yield 2018 -
Sales 2019 3,33 M
EBIT 2019 -71,2 M
Net income 2019 -70,2 M
Finance 2019 160 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 10,5x
Capitalization 195 M
More Financials
Company
Zafgen, Inc. is a biopharmaceutical company, which is engages in the development of therapeutics for both rare and prevalent metabolic diseases including type 2 diabetes, Prader-Willi syndrome, or PWS, and potentially other metabolically related disorders.It offers the ZGN-1061, a novel... 
More about the company
Latest news on ZAFGEN INC
06/23Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of Z..
GL
06/08ZAFGEN : Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everet..
AQ
06/07ZAFGEN, INC. : Change in Directors or Principal Officers, Submission of Matters ..
AQ
06/07Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy..
GL
05/31ZAFGEN : Expands Executive Leadership Team with Appointment of Brian McVeigh as ..
AQ
05/30ZAFGEN, INC. : Change in Directors or Principal Officers, Other Events, Financia..
AQ
05/30ZAFGEN : Expands Executive Leadership Team with Appointment of Brian McVeigh as ..
PU
05/30Zafgen, Inc. Expands Executive Leadership Team with Appointment of Brian McV..
GL
05/15ZAFGEN : Reports first quarter 2018 operating and financial results
AQ
05/10ZAFGEN : Management's Discussion and Analysis of Financial Condition and Results..
AQ
More news
Sector news : Bio Therapeutic Drugs
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/23Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of Z.. 
06/19The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs
3
06/07Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy.. 
06/05Zafgen Inc $ZFGN Expected to Post Earnings of -$0.59 Per Share  
06/05Get the latest news and updates for $XEL $EPIX $ZFGN $KNL $GABC automatically.. 
More tweets
Qtime:138
News from SeekingAlpha
06/15ZAFGEN : Second-Generation MetAP2 Inhibitors Likely To Unlock Substantial Interm.. 
05/12Zafgen's (ZFGN) CEO Jeff Hatfield on Q1 2018 Results - Earnings Call Transcri.. 
05/08Zafgen misses by $0.06 
04/27INSYS launches mid-stage study of CBD in rare obesity disorder 
03/15Zafgen (ZFGN) Presents At 38th Annual Cowen And Company Healthcare Conference.. 
Chart ZAFGEN INC
Duration : Period :
Zafgen Inc Technical Analysis Chart | ZFGN | US98885E1038 | 4-Traders
Technical analysis trends ZAFGEN INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 11,0 $
Spread / Average Target 55%
EPS Revisions
Managers
NameTitle
Jeffrey S. Hatfield Chief Executive Officer & Director
Thomas E. Hughes President, Chief Scientific Officer & Director
Peter Barrett Chairman
Patricia L. Allen CFO & Principal Accounting Officer
Dennis D. Kim Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ZAFGEN INC53.46%195
GILEAD SCIENCES-0.80%92 410
VERTEX PHARMACEUTICALS3.10%40 566
REGENERON PHARMACEUTICALS-11.70%35 172
GENMAB-3.97%9 557
SAREPTA THERAPEUTICS INC152.21%9 196